UNSPSC 51102844: Dexamethasone/neomycin/polymyxin b

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class OP350. This VA Drug Class (OP350) classifies this compound as belonging to the group ANTI-INFECTIVE/ANTI-INFLAMMATORY COMBINATIONS, TOPICAL OPHTHALMIC.

UNSPSC 51102844 Dexamethasone/neomycin/polymyxin b is a Commodity code that captures pharmaceutical products, but the recent state and local opportunities tagged under it show little activity directly aligned with this specific ophthalmic antibiotic combination. Instead, the four recorded opportunities span broader pharmacy procurement: emergency medical supplies (naloxone and drug deactivation systems), direct-to-manufacturer prescription programs, fire rescue medical consumables, and multi-state generic pharmaceutical cooperative purchasing. The actual buying pattern under this code reflects state and local government procurement of FDA-regulated pharmaceuticals and medical supplies across health departments, cooperative purchasing consortia, emergency services, and pharmacy benefit programs. Issuing bodies include state health and human services agencies (Texas HHS Commission, Minnesota Department of Administration), county health departments (Seminole County, Florida), city fire and rescue divisions (Tampa Fire Department), and multi-state cooperative purchasing alliances (MMCAP, serving Minnesota and Oregon). The absence of opportunities specifically for dexamethasone/neomycin/polymyxin b suggests this particular ophthalmic formulation sees limited recent competitive solicitation activity at the state and local level.

Geographic activity spans Florida (Seminole County), Texas (state-level HHS), Minnesota and Oregon (multi-state cooperative), and the broader coverage area of regional purchasing consortia. The most recent opportunities include Seminole County's IFB 60459723LAS (posted June 30, 2026, due July 26, 2023) for 1,900 units of naloxone and 800 safe drug deactivation systems with quarterly deliveries; the Texas HHS Commission's RFI HHS0017013 (posted April 3, 2026) on direct-to-manufacturer prescription capabilities; the City of Tampa's IFB 26-P-00145 (posted March 25, 2026, due March 13, 2026) for 169 line items of medical and first aid supplies for the Fire Department Rescue Division with an estimated contract value of $700,000 and a Small Local Business Enterprise set-aside; and MMCAP's RFP S1070000015802 (posted January 20, 2026, due March 26, 2026) for generic multi-source pharmaceuticals and OTC products distributed through three authorized wholesalers. The divergence between the code's nominal scope and recent opportunities suggests that dexamethasone/neomycin/polymyxin b procurement activity, if present, is not currently surfacing through competitive state and local solicitations.